GlassScriptPhysician profile
Malak Alaboudi
NPI 1487323457
$3,057.71
in general payments reported to CMS, 2019-2025
26 companies · $842 in 2025
The $842 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.78 · 2022: $476 · 2023: $558 · 2024: $1,099 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,499.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $566.30 | 2024-2025 | Briviact, Rystiggo, Zilbrysq |
| Novartis Pharmaceuticals Corporation | $442.96 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $290.60 | 2022-2025 | Wainua, Andexxa |
| Emd Serono, INC. | $253.33 | 2022-2025 | Mavenclad |
| Genentech USA, INC. | $233.20 | 2021-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Alexion Pharmaceuticals, INC. | $189.41 | 2021-2024 | Ultomiris |
| Pfizer INC. | $149.44 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $147.64 | 2022-2025 | Hyqvia |
| Jazz Pharmaceuticals INC. | $127.08 | 2023-2024 | |
| Averitas Pharma INC. | $110.24 | 2023-2025 | Qutenza |
| Lilly USA, LLC | $74.14 | 2024-2025 | Amyvid, Kisunla |
| Alnylam Pharmaceuticals INC. | $61.79 | 2025 | Onpattro |
| Lundbeck LLC | $59.94 | 2025 | Vyepti |
| Genzyme Corporation | $57.00 | 2022-2023 | |
| Amgen INC. | $48.75 | 2025 | Uplizna |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $39.15 | 2022 | |
| Argenx US, INC. | $34.94 | 2025 | Vyvgart Hytrulo |
| Abbvie INC. | $29.78 | 2023 | Botox |
| Sk Life Science, INC. | $20.87 | 2025 | |
| Tg Therapeutics, INC. | $20.24 | 2023 | |
| Janssen Biotech, INC. | $19.07 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $17.99 | 2025 | Austedo Xr |
| Biogen, INC. | $17.37 | 2022 | |
| Amylyx Pharmaceuticals, INC. | $16.90 | 2024 | Relyvrio |
| Horizon Therapeutics Plc | $15.90 | 2022 | |
| Tanabe Pharma America, INC. | $13.68 | 2025 | Radicava |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malak Alaboudi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.